Treatment in juvenile rheumatoid arthritis and new treatment options;Jüvenil idiyopatik artritte tedavi ve yeni tedavi seçenekleri

Turk Pediatri Arsivi

Volumn 50, Issue 1, 2015, Pages 1-10

  Kasapçopur, Özgür ^a   Barut, Kenan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Adalimumab; Anakinra; Anti TNF agents; Etanercept; Infliximab; Juvenile idiopatic arthritis; Kanakunimab; Pediatric rheumatology; Treatment

Indexed keywords

BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; HUMAN; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS;

EID: 84926632748     PISSN: 13060015     EISSN: 13086278     Source Type: Journal    
DOI: 10.5152/tpa.2015.2229     Document Type: Article

References (49)

1. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet 2011; 377; 2138-49.[CrossRef ]
2. Makay BB, Sözeri B, Özen S, Kasapçopur Ö. Jüvenil idyopatik artrit: tedavi uzlaşı rehberi. Çocuk Romatoloji Derneği Yayınları, 1. Deomed Yayıncılık, İstanbul 2013.
3. Makay B, Unsal E, Kasapcopur O. Juvenile idiopathic arthritis. World J Rheumatol 2013; 3: 16-24.[CrossRef ]
4. Luca NJ, Feldman BM. Disease activity measures in paediatric rheumatic diseases. Int J Rheumatol 2013; 2013: 715352.
5. Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009; 61: 658-66.[CrossRef ]
6. Ringold S, Bittner R, Neogi T, et al. Performance of rheumatoid arthritis disease activity measures and juvenile arthritis disease activity scores in polyarticular-course juvenile idiopathic arthritis: analysis of their ability to classify the American College of Rheumatology pediatric measures of response and the preliminary criteria for flare and inactive disease. Arthritis Care Res 2010; 62: 1095-102.[CrossRef ]
7. Wallace CA, Giannini EH, Huang B, et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res 2011; 63: 929-36.[CrossRef ]
8. Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31: 2290-4.
9. Ozdogan H, Ruperto N, Kasapcopur O, et al. The Turkish version of the childhood health assessment questionnaire (CHAQ) and the child health questionnaire (CHQ). Clin Exp Rheumatol 2001; 19: S158-62.
10. Tarakci E, Baydogan SN, Kasapcopur O, Dirican A. Crosscultural adaptation, reliability, and validity of the Turkish version of PedsQL 3.0 Arthritis Module: a quality-of-life measure for patients with juvenile idiopathic arthritis in Turkey. Qual Life Res 2013; 22: 531-6.[CrossRef ]
11. Guzman J, Oen K, Tucker L B, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis 2014; 2014: 205372.
12. Kessler EA, Becker ML. Therapeutic advancements in juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol 2014; 28: 293-313.[CrossRef ]
13. Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol 2014; 12: 13.[CrossRef ]
14. Gowdie PJ, Tse SM. Juvenile idiopathic arthritis. Pediatr Clin North Am 2012; 59: 301-27.[CrossRef ]
15. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 342: 763-9.[CrossRef ]
16. Horneff G, Ebert A, Fitter S, et al. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis. Rheumatology (Oxford) 2009; 48: 916-9.[CrossRef ]
17. Prince FH, Twilt M, Jansen-Wijngaarden NC, et al. Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study. Ann Rheum Dis 2007; 66: 704-5.[CrossRef ]
18. Özdoğan H, Kasapçopur Ö. Jüvenil idyopatik artrit tedavisinde anti-TNF ajanlar. Turkiye Klinikleri J Rheumatol-Special Topics 2010: 3; 40-8.
19. Tugal-Tutkun I, Ayranci O, Kasapcopur O, Kir N. Retrospective analysis of children with uveitis treated with infliximab. J AAPOS 2008; 12: 611-3.[CrossRef ]
20. Tse SM, Burgos-Vargas R, Laxer RM. Anti-tumor necrosis factor α blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum 2005; 52: 2103-8.[CrossRef ]
21. Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlledtrial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007; 56: 3096-106.[CrossRef ]
22. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359: 810-20.[CrossRef ]
23. Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German biologics JIA registry. Arthritis Rheumatol 2014; 66: 2580-9.[CrossRef ]
24. Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease modifying therapy in systemic juvenile idiopathic arthritis. Arthritis Rheum 2011; 63: 545-55.[CrossRef ]
25. Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011; 70: 747-54.[CrossRef ]
26. Gattorno M, Piccini A, Lasigliè D, et al The pattern of response to antiinterleukin-1 treatment distinguishes two subsets of patients with systemic onset juvenile idiopathic arthritis. Arthritis Rheum 2008; 58: 1505-15.[CrossRef ]
27. Ilowite N, Porras O, Reiff A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009; 28:129-37.[CrossRef ]
28. Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011; 63: 545-55.[CrossRef ]
29. Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50: 1412-9.[CrossRef ]
30. Ruperto N, Quartier P, Wulffraat N, et al. A phase II study to evaluate dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012; 64: 557-67.[CrossRef ]
31. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2396-406.[CrossRef ]
32. Lovell DJ, Giannini EH, Kimura Y, et al. Preliminary evidence for sustained bioactivity of IL-1 Trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis (SJIA). Arthritis Rheum 2007; 56: S515.
33. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American college of rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res (Hoboken) 2013; 65: 1551-63.[CrossRef ]
34. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebocontrolled, withdrawal phase III trial. Lancet 2008; 371: 998-1006.[CrossRef ]
35. De Benedetti F, Brunner HI, Ruperto N. et al. Tocilizumab for systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2385-95.[CrossRef ]
36. Imagawa T, Yokota S, Mori M, et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol 2012; 22: 109-15.[CrossRef ]
37. Brunner H, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withrdawal trial. Ann Rheum Dis 2014 M 16 (e pub).
38. Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372: 383-91.[CrossRef ]
39. Ruperto N, Lovell DJ, Quartier P, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010; 62: 1792-802.[CrossRef ]
40. Ruperto N, Lovell DJ, Li T, et al. Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2010; 62: 1542-51.[CrossRef ]
41. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis ansystemic features. Arthritis Care Res 2011; 63: 465-82.[CrossRef ]
42. Alexeeva EI, Valieva SI, Bzarova TM, et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol 2011; 30: 1163-72.[CrossRef ]
43. Kawalec P, Mikrut A, Wisniewska N, et al. The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 2013; 32: 1415-24.[CrossRef ]
44. Pfizer. An open-label multiple dose study to evaluate the pharmacokinetics, safety and tolerability of CP-690,550 in pediatric patients from 2 to less than 18 years of age with juvenile idiopathic arthritis (JIA). In: ClinicalTrials. gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2014 Feb 11]. Available from: http:/?clinicaltrials.gov/show/NCT01513902.
45. Kılıc O, Kasapcopur O, Camcioglu Y, et al. Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic diseases? Rheum Int 2012; 32: 2675-9.[CrossRef ]
46. Kiray E, Kasapcopur O, Bas V. Purified protein derivative response in juvenile idiopathic arthritis. J Rheumatol 2009; 36: 2029-32.[CrossRef ]
47. Cron RQ, Beukelman T. Guilt by association-what is the true risk of malignancy in children treated with etanercept for JIA? Pediatr Rheumatol Online J 2010; 8: 23.[CrossRef ]
48. Horneff G, Foeldvari I, Minden K, et al. Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology (Oxford) 2011; 50: 230-6.
49. Simard JF, Neovius M, Hagelberg S, et al. Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 2010; 62: 3776-82.